Clinical Data, GWU to Study Benefits of Using PGx to Dose Warfarin | GenomeWeb
NEW YORK (GenomeWeb News) — Clinical Data’s PGxHealth division will work with clinical researchers at George Washington University to study the effectiveness of using genomic testing to guide dosing decisions for the widely used anticoagulant warfarin, the company said yesterday.
 
The studies will use Clinical Data’s PGxPredict:Warfarin in a trial involving 80 post-surgical GWU patients to “evaluate the potential clinical, safety, and treatment-time benefits of using the genetic test to determine optimal warfarin dosing.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.